Supernus Pharmaceuticals Inc banner

Intrinsic Value

The intrinsic value of Supernus Pharmaceuticals Inc (S49) under the Base Case is 59.47 EUR per share. Compared with the current market price of 37.4 EUR, the stock appears Undervalued by 37% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

S49 Intrinsic Value
€59.47
Undervaluation 37%
Intrinsic Value
Price €37.4
Alert me when S49 is below its intrinsic value
Today €35.68 · 4.6% below the current price

S49 is cheaper than usual. This is its cheapest valuation in the past 5 years.

Alternatives to S49

Fundamental Analysis

What Supernus Pharmaceuticals Does

Pharmaceuticals Health Care

Supernus Pharmaceuticals is a specialty drug company that makes prescription medicines for central nervous system disorders, especially attention deficit hyperactivity disorder, epilepsy, migraine, and movement disorders. Its main products are branded medicines sold through pharmacies to patients with prescriptions from doctors. The company earns money when wholesalers and pharmacies buy those drugs and move them into the prescription chain.

Headquarters
United States of America US
Employees
778
IPO date
Dec 28, 2010
Read the full company overview
View Company Overview

Supernus Pharmaceuticals has no economic moat

No Moat Narrow Wide

Supernus Pharmaceuticals Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.

Read the full moat analysis
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Ownership

Supernus Pharmaceuticals insiders are selling within their usual range

Insider trading · Last trade on Mar 18, 2026

Sold $6.8m 7 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Continue S49 Research

Decided on Supernus Pharmaceuticals? Get an email when S49 reaches the price you’d buy at. Free with an account.

Other Supernus Pharmaceuticals listings

What is the Intrinsic Value of one S49 stock?

The intrinsic value for Supernus Pharmaceuticals Inc (S49) under the Base Case is 59.47 EUR.

Is S49 stock undervalued or overvalued?

Compared with the current market price of 37.4 EUR, the stock appears Undervalued by 37% .

How reliable are our estimates? See how past valuations played out
Back to Top